Verification of the analytical performance of the urine cannabinoids immunoassay on the Abbott Alinity ci ®

The precision and reliability of the urine cannabinoids assay on the Abbott Alinity ci® analyzer were systematically evaluated. The study was conducted over 30 days in the biochemistry laboratory of Mohammed VI University Hospital. Two phases were carried out: reproducibility assessment involving daily measurements across low and high cannabinoid levels, and repeatability testing involving 30 replicates per sample. A homogeneous immunoenzymatic approach was employed for cannabinoid quantification. Data analysis utilized the BYG middleware and adhered to the manufacturer standards. For reproducibility, the coefficient of variation (CV) values were low, ranging from 2,6% to 3,1%. Repeatability CV values were also low, varying from 2,8% to 3,7%. Results were consistent with quality control limits, confirming the assay's precision and reliability. This study highlights the robustness of the immunoenzymatic method on the Alinity ci® platform for urine cannabinoid analysis, with significant implications for accurate patient care. By adhering to stringent analytical performance verification protocols, laboratories ensure dependable and clinically meaningful outcomes. This research contributes to the foundational knowledge supporting the reliability of urine cannabinoid measurement methodologies.